Patient description: A 22-year-old Caucasian man came to the Clinic with a history of tremors since a year ago. The tremor was first in his right hand while holding something. Later the tremor became continuous and extended to both hands and legs and even at rest. The Kayser-Fleischer' ring was detected in the ophthalmologic exam. The physical exam revealed jaundice, hepatosplenomegaly and hypotonia of the upper limbs. He had a constant smile on his face, however, he has aggressive behavior according to his parents' explanation. His laboratory study was significant for a low serum caeruloplasmin (0.05 g/l), and a raised 24 hour urine copper excretion (120 μg/24 h). Wilson disease was confirmed by high liver copper concentration (305 μg/g dry weight of liver).

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  End Stage Liver Disease Adults of either gender and ages 18 to 70 years old Subjects must have a diagnosis of end-stage liver disease (ESLD) due to alcohol, chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, autoimmune hepatitis, primary sclerosis cholangitis, primary biliary cirrhosis (cholangitis), cirrhosis as the result of Wilson disease, hemochromatosis, sarcoidosis and alpha 1 antitrypsin deficiency, cryptogenic cirrhosis and nonalcoholic steatohepatitis cirrhosis with a MELD-Na score >10 to <25 at screening Subjects have a Body Mass Index (BMI) <35 Subjects with HCV associated ESLD must have been treated and demonstrate 24 weeks of negative HCV RNA Subjects with HBV must be on stable therapy for 6 months and have HBV DNA <500 c/mL Women of childbearing potential (WOCBP) or sexual partners of male subjects who are WOCBP must be able and willing to use at least 1 highly effective method of contraception during the study and for 1 month after the last study visit. A female subject is considered to be a WOCBP after menarche and until she is in a postmenopausal state for 12 months or otherwise permanently sterile (for which acceptable methods hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) Subject must have stable control of portal hypertension and upper gastrointestinal bleeding with medical therapy and/or endoscopic therapy If the subject has undergone a transjugular intrahepatic portosystemic shunt (TIPS) procedure for the clinical management of portal hypertension, they must be stable for at least 1 month after the successful TIPS procedure, and not experiencing serious complications from the TIPS procedure itself (e.g., infection and intractable hepatic encephalopathy) Subject must have serum BUN <80 mg/dL Subject must have a eGFR <45 mL/min/1.73m2  Subject has primary hepatic neoplasms (hepatocellular carcinoma and cholangiocarcinoma) Subject has active and/or uncontrolled severe infections requiring hospitalization and prolonged antimicrobial therapy Subject has renal failure with BUN >= 80 mg/dL Subject has a eGFR >= 45 mL/min/1.73m2 Subject has severe coagulopathy (INR >2, and/or platelet count <50,000/μL) Subject has psychiatric and/or social issues that could lead to noncompliance Subject has an extrahepatic neoplastic disease requiring active chemotherapy, immunotherapy, and/or surgical resection Subject has previously treated neoplastic disease with less than a 2-year cancer free period Subject is pregnant or lactating Subject has known hypersensitivity to human serum albumin